Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Pharmaceutical Co. Ltd.

www.otsuka.co.jp/en/

Latest From Otsuka Pharmaceutical Co. Ltd.

Merck & Co Takes Up Astex/Taiho SHP2 Program

Merck & Co joins ranks of big pharma firms pursuing the SHP2 area of oncology as it picks up global rights to a portfolio of inhibitors originating from two affiliates of Japan's Otsuka Pharmaceutical.

Deals Research & Development

M&A Already Underway As Angelini Acquires Arvelle

2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.

M & A Neurology

Astellas' Phase III Front-Line AML Study Of Xospata Fails

One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.

BioPharmaceutical Clinical Trials

Lundbeck's Vyepti Sales Pick Up Against Pandemic Headwinds

Lundbeck also makes progress in the third quarter with its early clinical-stage neuroscience candidates and indication extension studies for its psychiatry products, while confirming and narrowing  revenues and earnings forecasts for the year.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
UsernamePublicRestriction

Register